Jun 24, 2026 04:15AM
May 28, 2026 08:00AM
Mar 24, 2026 04:19AM
Mar 23, 2026 09:38PM
Mar 19, 2026 08:53AM
Jan 20, 2026 06:41AM
Dec 17, 2025 07:00AM Sol-Gel discontinues SGT-210 development after phase 1b trial fails
Dec 17, 2025 07:00AM
Nov 20, 2025 07:30AM
Sep 4, 2025 07:02AM
Sep 4, 2025 07:00AM
Aug 15, 2025 07:00AM
May 23, 2025 07:15AM
May 1, 2025 07:09AM Sol-Gel Technologies Ltd. (SLGL) Announces 10-for-1 Reverse Share Split
May 1, 2025 07:00AM
Apr 17, 2025 08:42AM
Apr 17, 2025 08:40AM
Nov 20, 2024 07:02AM
Nov 20, 2024 07:00AM
Nov 15, 2024 07:00AM
Aug 17, 2024 11:27AM UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Aug 16, 2024 07:00AM
Jul 25, 2024 07:03AM
Jul 25, 2024 07:00AM
Jul 15, 2024 07:01AM
Jul 15, 2024 07:00AM
May 28, 2024 07:04AM
May 28, 2024 07:00AM Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 20, 2024 07:00AM
May 16, 2024 06:00AM
May 16, 2024 06:00AM
Apr 1, 2024 07:03AM
Apr 1, 2024 07:00AM
Mar 13, 2024 07:00AM
Nov 30, 2023 07:00AM Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Nov 28, 2023 08:06AM
Nov 9, 2023 07:00AM
Aug 30, 2023 08:00AM
Aug 10, 2023 07:00AM
Jun 6, 2023 07:30AM
Jun 6, 2023 07:04AM
Jun 6, 2023 07:00AM Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
May 12, 2023 07:00AM
Mar 20, 2023 07:00AM
Mar 10, 2023 07:00AM
Jan 27, 2023 07:29AM
Jan 27, 2023 07:29AM
Jan 27, 2023 07:00AM
Jan 27, 2023 07:00AM Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Aug 29, 2022 06:27AM

325,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All